Searchable abstracts of presentations at key conferences in endocrinology

ea0035p62 | Adrenal Medulla | ECE2014

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

Martino Maria Cristina De , Feelders Richard A. , Dogan Fadime , Koetsveld Peter M. van , Krijger Ronald R. De , Janssen Joseph A M J L , Sprij-Mooij Diana , Lamberts Steven W. J. , Herder Wouter W de , Colao Annamaria , Pivonello Rosario , Hofland Leo J

The mTOR and IGF pathways have been suggested to play a role in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus (S) and everolimus (E), as well as IGF1R antagonists could be a potential novel treatment for malignant PPC.The aim of this study was to evaluate the expression of the main components of the IGF/mTOR pathway in human PCC and to investigate the effects of the mTOR inhibitors S and E and of the IGF1R/insulin receptor (I...

ea0016p564 | Obesity | ECE2008

Leptin decreases and glucose deprivation increases the generation of the soluble leptin receptor (sOb-R) in a cell model

Schaab Michael , Morawe Daniel , Klammt Jurgen , Wilfert Wolfgang , Thiery Joachim , Kratzsch Jurgen

Objective: The soluble leptin receptor (sOb-R) is generated by ectodomain shedding of the membrane-associated Ob-R and may modulate leptin action in metabolic dysregulations. The objective of our study was to investigate whether or not sOb-R generation may be induced by indicators of energy availability or metabolic regulators in a cell model.Material and methods: The four human Ob-R isoforms were cloned, characterized by binding experiments with 125-iod...

ea0003oc12 | Endocrine Neoplasia | BES2002

Ghrelin inhibits proliferation of breast cell lines acting via the growth hormone secretagogue receptor (GHS-R)

Taylor J , Hughes B , Sheppard M , Stewart P , Toogood A

Ghrelin, the natural ligand for the GHS-R, modulates proliferation in cell lines derived from malignant breast tissue. It has been suggested that this action is independent of the GHS-R. We have previously demonstrated that MCF7 cells expressed ghrelin but not GHS-R mRNA and MDA-MB231 cells expressed GHS-R but not ghrelin mRNA. To determine whether ghrelin modulates proliferation in MCF7 and MDA-MB231 cells we performed proliferation assays treating with saline, 1 and 10nM ghr...

ea0020p596 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

GH deficiency in HIV-infected patients with lipodystrophy: preliminary data on the effects of r-hGH treatment on body composition

Zirilli Lucia , Orlando Gabriella , Brigante Giulia , Squillace Nicola , Diazzi Chiara , Carani Cesare , Guaraldi Giovanni , Rochira Vincenzo

Introduction: HIV-infected patients often display a moderate to severe GH deficiency (GHD). To investigate the effects of r-hGH on hormonal parameters and body composition in patients with HIV-related lipodystrophy (HIV-r-L) and concomitant GHD, we studied 60 patients with HIV-r-L, 28 male and 32 females aged 18–65 years. According to their response to GHRH+Arginine (GH peak assumed to be normal when >7.5 ng/ml) patients were assigned to the following 3 groups: Group ...

ea0063p255 | Pituitary and Neuroendocrinology 1 | ECE2019

Trunk fat increase is prevented both in patients undergoing long-lasting continuous r-hGH therapy and in those who discontinued r-hGH compared to untreated patients: results from baseline data of the MAGHD study

Monzani Maria Laura , Magnani Elisa , Diazzi Chiara , Pederzoli Simone , Volpi Laura , Rochira Vincenzo

Background: Adult growth hormone (GH) deficiency (AGHD) is related with alterations in body composition, increased abdominal and visceral adiposity, adverse change in lipid and carbohydrate metabolism, and reduction of bone mineral density (BMD).Aim: To compare baseline outcomes concerning body composition and biochemical/hormonal data among adult patients with AGHD referring to a single endocrinological center and grouped according to their history of r...

ea0063p144 | Diabetes, Obesity and Metabolism 1 | ECE2019

The psychometric adaptation of the Russian version of the Diabetes Eating Problem Survey–Revised (DEPS-R)

Labashova Veranika , Shepelkevich Alla , Dydyshka Yulia

Objectives: Eating disorders often co-occur with diabetes, and this comorbidity is associated with severe medical complications. The DEPS-R is a 16-item diabetes-specific self-report measure of disordered eating that can be completed in <10 min. The purpose of the study was to translate and validate the Russian version of the Diabetes Eating Problem Survey–Revised (DEPS-R).Methods: 372 patients with diabetes mellitus using insulin injections par...

ea0002oc12 | Neuroendocrinology | SFE2001

Tissue distribution of the mRNA of the novel endocrine regulator ghrelin and its receptor, GHS-R

Gnanapavan S , Grossman A , Korbonits M

Ghrelin is a novel growth hormone-releasing peptide, recently identified in the rat stomach as the endogenous ligand for the growth hormone secretagogue-receptor (GHS-R). Previously, regulation of GH release was thought to occur primarily via a phasic interaction between two hypothalamic neuropeptides, GHRH and somatostatin. It is now thought that ghrelin is an important third factor in the regulatory pathway. In addition to its GH-releasing activity ghrelin may have other act...

ea0030oc2.7 | Oral Communications 2 | BSPED2012

Growth, GH–IGF1 status and response to r-hGH therapy in 3-M syndrome, related to mutation status

Sakhinia Faezeh , Hanson Dan , Murray Philip , Kirk Jeremy , Cole Trevor , Skae Mars , Banerjee Indi , Padidela Raja , Patel Leena , Clayton Peter

Background: 3-M syndrome is associated with severe proportionate pre- and postnatal growth restriction, and is caused by mutations in CUL7, OBSL1, or CCDC8 genes.Aims and methods: To define baseline growth and GH–IGF1 axis status as well as response to r-hGH in relation to mutation status in 3-M children, using retrospective analysis of data from clinical notes.Results: 50 individuals (19 CUL7, 19 <...

ea0030p53 | (1) | BSPED2012

High rates of non adherence to daily r-hGH injections revealed by the easypod electronic dose record

Bryan Sinead M

Background and aims: Non-adherence to daily subcutaneous GH (r-HGH) administration may account for discrepancies between dose prescription, growth response and serum IGF1 levels but is difficult to determine. The electronic r-HGH auto-injector Easypod device has the only inbuilt retrievable dosing record, with which we aimed to assess adherence.Method: Over a 4 month period, we retrospectively retrieved dose history data in 25 clinic patients aged 10&#15...

ea0015p305 | Steroids | SFEBES2008

Testosterone levels in hypogonadal men treated with Nebido® is influenced by age, body composition and baseline testosterone

Moisey Robert , Swinburne Julie , orme Steve

Nebido (testosterone undecanoate, 1000 mg) is a new, long acting, intramuscular (IM) preparation of testosterone (T) that can be administered every 10–14 weeks. We conducted a study to evaluate the factors that influence serum T levels after commencing Nebido and may therefore help clinicians estimate dosing frequency for this therapy.Following the recommended loading regimen, 51 hypogonadal men (35, 68.6% secondary hypogonadism) had two injections ...